A long-lasting response to sorafenib treatment in an advanced hepatocellular carcinoma patient(296 views) Di Lorenzo G, Imbimbo M, Leopardo D, Marciano R, Federico P, Buonerba C, Salvatore B, Marinelli A, Palmieri G. A
Int J Immunopathol Pharmacol (ISSN: 0394-6320), 2010 Jul; 23(3): 951-954.
Keywords: Advanced Disease, Hepatocellular Carcinoma, Sorafenib, Adult, Advanced Cancer, Article, Cancer Survival, Case Report, Chemoembolization, Drug Dose Reduction, Drug Efficacy, Drug Withdrawal, Febrile Neutropenia, Follow Up, Hand Foot Syndrome, Heart Infarction, Human, Human Tissue, Liver Biopsy, Liver Cell Carcinoma, Multiple Cycle Treatment, Priority Journal, Progression Free Survival, Treatment Response, Treatment Withdrawal, Antineoplastic Agents, Benzenesulfonates, Disease Progression, Liver Neoplasms, Middle Aged, Myocardial Infarction, Pyridines, Tumor Markers, Biological,
Affiliations: *** IBB - CNR ***
Department of Endocrinology and Clinical Oncology, Referential Rare Tumors Center, University Federico II, Naples, Italy
Radiology Division, University Federico II, Naples, Italy
References: Shariff, M.I., Cox, I.J., Gomaa, A.I., Khan, S.A., Gedroyc, W., Taylor-Robinson, S.D., Hepatocellular carcinoma: Current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics (2009) Expert Rev Gastroenterol Hepatol, 3, pp. 353-36
Llovet, J.M., Ricci, S., Mazzaferro, V., Sorafenib in advanced hepatocellular carcinoma (2008) N Engl J Med, 359, pp. 378-390
Cheng, A.L., Kang, Y.K., Chen, Z., Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomized, double-blind, placebo-controlled trial (2009) Lancet Oncol, 10, pp. 25-34
Orphanos, G.S., Ioannidis, G.N., Ardavanis, A.G., Cardiotoxicity induced by tyrosine kinase inhibitors (2009) Acta Oncol, pp. 48964-48970
Di Lorenzo, G., Autorino, R., Bruni, G., Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: A multicenter analysis (2009) Ann Oncol, 20, pp. 1535-1542
Shariff, M. I., Cox, I. J., Gomaa, A. I., Khan, S. A., Gedroyc, W., Taylor-Robinson, S. D., Hepatocellular carcinoma: Current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics (2009) Expert Rev Gastroenterol Hepatol, 3, pp. 353-36
Llovet, J. M., Ricci, S., Mazzaferro, V., Sorafenib in advanced hepatocellular carcinoma (2008) N Engl J Med, 359, pp. 378-390
Cheng, A. L., Kang, Y. K., Chen, Z., Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomized, double-blind, placebo-controlled trial (2009) Lancet Oncol, 10, pp. 25-34
Orphanos, G. S., Ioannidis, G. N., Ardavanis, A. G., Cardiotoxicity induced by tyrosine kinase inhibitors (2009) Acta Oncol, pp. 48964-48970
A long-lasting response to sorafenib treatment in an advanced hepatocellular carcinoma patient